Castrate-resistant prostate cancer (CRPC) progression is a complex process by which
prostate cells acquire the ability to survive and proliferate in the absence or under very low …

Castrate-resistant prostate cancer (CRPC) is the fatal form of prostate cancer. Although
reactivation of androgen receptor (AR) occurs following androgen deprivation, the precise …

Current treatment strategies provide minimal results for patients with castration-resistant
prostate cancer (CRPC). Attempts to target the androgen receptor have shown promise, but …

Background: Although androgen deprivation therapy for advanced prostate cancer initially
exerts excellent anticancer effects, most prostate cancer treated with androgen deprivation …

As prostate cancer progresses to castration-resistant disease, there is an increase in signal
transduction activity. Most castration-resistant prostate tumors continue to express the …

Reactivation of androgen receptor (AR) may drive recurrent prostate cancer in castrate
patients. Ack1 tyrosine kinase is overexpressed in prostate cancer and promotes castrate …

Prostate cancer (PCA) is the second leading cause of cancer‐related deaths in men in the
United States. It is natural for a hormone‐driven malignancy such as prostate cancer that …

The Src-related protein kinase Lyn plays an important role in B-cell activation. However,
several lines of evidence suggest that it is also involved in the control of cellular proliferation …

SRC kinase is activated in castration resistant prostate cancer (CRPC), phosphorylates the
androgen receptor (AR), and causes its ligand-independent activation as a transcription …

Androgens and androgen receptors play essential roles in the development and
progression of prostate cancer, a disease that claims roughly 28,000 lives annually. In …